|

APG-3288 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Ascentage Pharma Group Inc.1

Indications

  • Relapsed/Refractory Follicular Lymphoma (FL)1
  • Relapsed/Refractory Marginal Zone Lymphoma (MZL)1
  • Relapsed/Refractory Waldenström Macroglobulinemia (WM)1
  • Relapsed/Refractory Mantle Cell Lymphoma (MCL)1
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)1

Los Angeles, California1 trial

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.